The rare kidney diseases market was valued at USD 3.07 Billion in 2024, driven by the growing incidence of rare kidney diseases and the advances in treatment options across the 8 major markets. The market is anticipated to grow at a CAGR of 5.80% during the forecast period of 2025-2034, with the values likely to reach USD 5.40 Billion by 2034.
Base Year
Historical Year
Forecast Year
In September 2024, the FDA's approval of Filspari from Travere Therapeutics represents a major advancement in the rare kidney disease treatment, offering a non-immunosuppressive therapy for IgA nephropathy that targets disease progression, fostering market expansion and therapeutic innovation.
Improved awareness among healthcare professionals and patients about rare kidney diseases is leading to earlier diagnosis, which is poised to augment market demand in the coming years.
The continuous research and development initiatives aimed at enhancing treatment options for rare kidney diseases are expected to elevate the market value during the forecast period.
Value in USD Billion
2025-2034
Rare Kidney Diseases Market Outlook
*this image is indicative*
Rare kidney diseases are marked by insufficient kidney performance, resulting in the accumulation of waste and health complications. These rare kidney disorders frequently have genetic causes and encompass conditions such as IgA nephropathy, lupus nephritis, and focal segmental glomerular sclerosis, among others. IgA nephropathy is characterized by the buildup of antibodies in kidney tissues, leading to inflammation, and can be managed with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers. Management involves different therapeutic agents administered orally, intravenously, or subcutaneously. The market is projected to expand as cases of chronic kidney disease increase.
Surge in Rare Kidney Diseases to Boost Market Growth
The growing incidence of rare kidney diseases, such as Alport syndrome and Fabry disease, is a significant driver of the rare kidney diseases market. According to a UCLA Health report, Alport syndrome affects an estimated 30,000 to 60,000 individuals in the United States, underscoring the demand for innovative diagnostics and therapies. This increasing incidence accelerates research, investment, and advancements in specialized treatments to address critical unmet needs.
The market is witnessing several trends and developments to improve the current scenario. Some of the notable trends are as follows:
The market report offers a detailed analysis of the market based on the following segments:
Market Breakup by Drug Class
Market Breakup by Indication
Market Breakup by Distribution Channel
Market Breakup by Region
Segmentation Based on Drug Class of Molecule to Witness Substantial Growth
The market based on the drug class is divided into enzyme replacement therapy, monoclonal antibodies, and others. Enzyme replacement therapy is expected to lead the rare kidney disease market due to its established efficacy in treating conditions like Fabry disease and cystinosis. Advances in therapeutic formulations and the approval of novel enzyme-based treatments further enhance its market share, making it a preferred choice among healthcare providers for managing rare kidney diseases.
Based on the regions, the market is segmented into the United States, EU-4 (Germany, France, Italy, Spain), the United Kingdom, Japan, and India. The United States is anticipated to dominate the rare kidney disease market share owing to greater healthcare awareness, enhanced diagnostics, and substantial research funding. At the same time, the EU-4 market, especially in Germany, France, and Spain, is anticipated to expand significantly due to the increasing disease prevalence and government funding and initiatives.
The key features of the market report comprise patent analysis, clinical trial analysis, grants analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:
Alexion Pharmaceuticals, a subsidiary of AstraZeneca located in Boston, specializes in orphan drugs for rare conditions, with a particular emphasis on atypical hemolytic uremic syndrome (aHUS). This extremely uncommon genetic disorder can lead to severe kidney harm due to unchecked complement activation. The company is engaged in developing innovative therapies to reduce thrombotic microangiopathy risks and improve patients' quality of life.
Mallinckrodt Pharmaceuticals plc, a company with American and Irish roots, focuses on the development, production, and distribution of specialty pharmaceuticals and imaging agents. They are actively involved in rare kidney diseases with the FDA's endorsement of Terlivaz® for hepatorenal syndrome, marking the first successful therapy for this severe condition.
Novartis AG, based in Switzerland, is making progress in the rare kidney disease market with two Phase III clinical studies. The investigational medication, atrasentan, showed a considerable decrease in proteinuria among patients with IgA nephropathy.
Apellis Pharmaceuticals, Inc. is a global biopharmaceutical firm focused on creating pioneering treatments. In partnership with Sobi, they focus on uncommon kidney disorders such as C3 glomerulopathy and IC-MPGN. The trial for Sobi and Apellis’ pegcetacoplan showed a 68% decrease in proteinuria, which may slow disease advancement and give hope to patients.
*Please note that this is only a partial list; the complete list of key players is available in the full report. Additionally, the list of key players can be customized to better suit your needs.*
Other key players in the market include Pfizer Inc., Amicus Therapeutics, Inc., Chinook Therapeutics, Vertex Pharmaceuticals, and Kyowa Kirin Co, Ltd.
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
| REPORT FEATURES | DETAILS |
| Base Year | 2024 |
| Historical Period | 2018-2024 |
| Forecast Period | 2025-2034 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Drug Class |
|
| Breakup by Indication |
|
| Breakup by Distribution Channel |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
Datasheet
One User
USD 3,299
USD 2,969
tax inclusive*
Single User License
One User
USD 5,499
USD 4,969
tax inclusive*
Five User License
Five User
USD 6,999
USD 5,949
tax inclusive*
Corporate License
Unlimited Users
USD 8,199
USD 6,969
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
Share